Overview
DelRicht Research connects volunteers with no-cost access to advanced medical treatments and clinical trials so they can participate in the next generation of medicine today. It works by pairing individuals who want to take an active role in their health care with ongoing or upcoming studies and therapies, allowing participants to access promising options before they are widely available, at no cost to them. The company differentiates itself by removing financial barriers to cutting-edge treatments and focusing on empowering patients to participate directly in the development of new therapies. Its goal is to shorten the time it takes for medical discoveries to reach patients by accelerating access to experimental options and collecting real-world experiences to speed broader adoption.
Work here?Claim your company
Simplify's take
What believers are saying
- DelRicht enrolled 300% of goal in a Phase 3 obesity and T2DM trial on September 17, 2026.
- It enrolled 212.3% of goal in a Phase 2b CSU trial and 243.1% in obesity.
- November 5, 2026 gout coverage highlights over 10 gout trials and 550 participants enrolled.
What critics are saying
- Indeed reviewers on August 15, 2026 reported layoffs without notice and overwork.
- DelRicht owns no obvious proprietary drugs, so sponsor demand can vanish between trial cycles.
- Heavy dependence on obesity and cardiometabolic studies leaves the company exposed if major sponsors shift vendors.
What makes DelRicht Research unique
- DelRicht ran seven sites, reached first activation, and randomized first in a CSU trial on October 22, 2026.
- Its network claims 96% enrollment success and 91% retention across recent studies.
- It embeds specialty investigators across obesity, gout, and dermatology instead of using generic recruiting sites.
Help us improve and share your feedback! Did you find this helpful?